Enlivex Therapeutics Ltd. ENLV
We take great care to ensure that the data presented and summarized in this overview for Enlivex Therapeutics Ltd. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ENLV
View all-
Armistice Capital, LLC New York, NY2.14MShares$2.65 Million0.06% of portfolio
-
Morgan Stanley New York, NY246KShares$304,7340.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny74.8KShares$92,7380.0% of portfolio
-
Sigma Investment Counselors Inc30KShares$37,2000.0% of portfolio
-
Xtx Topco LTD London, X022.7KShares$28,0970.0% of portfolio
-
Act Capital Management, LLC Wayne, PA15KShares$18,6000.09% of portfolio
-
Goldman Sachs Group Inc New York, NY13.9KShares$17,2790.0% of portfolio
-
Geode Capital Management, LLC Boston, MA10.4KShares$12,9200.0% of portfolio
-
Wells Fargo & Company San Francisco, CA9.18KShares$11,3880.0% of portfolio
-
Group One Trading, L.P. Chicago, IL5.73KShares$7,1050.0% of portfolio
Latest Institutional Activity in ENLV
Top Purchases
Top Sells
About ENLV
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Insider Transactions at ENLV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|